Vol 20, No 1 (2017)
Review paper
Published online: 2017-01-31

open access

Page views 7963
Article views/downloads 6602
Get Citation

Connect on Social Media

Connect on Social Media

Breast cancer: early diagnosis and effective treatment by drug delivery tracing

Mahdiyeh Shamsi, Jalil Pirayesh Islamian
Pubmed: 28218347
Nucl. Med. Rev 2017;20(1):45-48.

Abstract

Breast cancer is the most frequent cancer in women and it is the main reason of cancer-related deaths of women worldwide. Different types of breast cancer diagnostic examinations are also available, such as mammography, MRI, biopsy, ultrasound and molecular imaging. Radionuclide-based imaging methods including SPECT and PET are useful in early diagnosis and treatment of the cancer. The radiolabeling of chemo drugs with nanoparticles should be recommended from the standpoint of an early diagnosis and effective treatment of breast cancer.

Article available in PDF format

View PDF Download PDF file

References

  1. Aghaee F, Pirayesh Islamian J, Baradaran B. Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy. J Breast Cancer. 2012; 15(2): 141–147.
  2. Dias MF, Sousa E, Cabrita S, et al. Chemoprevention of DMBA-Induced Mammary Tumors in Rats by a Combined Regimen of Alpha-Tocopherol, Selenium, and Ascorbic Acid. Breast J. 2000; 6(1): 14–19.
  3. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2): 74–108.
  4. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000; 321(7261): 624–628.
  5. de la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993; 341(8852): 1039–1043.
  6. http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf.
  7. www.cancer.org.
  8. Chen Y, Huang ZW, He L, et al. Synthesis and evaluation of a technetium-99m-labeled diethylenetriaminepentaacetate-deoxyglucose complex ([99mTc]-DTPA-DG) as a potential imaging modality for tumors. Appl Radiat Isot. 2006; 64(3): 342–347.
  9. Annex I. Recent developments in nuclear medicine for cancer management: from nuclear medicine to molecular imaging. Nucl Technol. 2010; 57.
  10. Willmann JK, van Bruggen N, Dinkelborg LM, et al. Molecular imaging in drug development. Nat Rev Drug Discov. 2008; 7(7): 591–607.
  11. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov. 2003; 2(2): 123–131.
  12. Shan L. 99mTc-Labeled doxorubicin. In: Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information (US) 2004-2013.
  13. Lindner M, McArthur R, Deadwyler S, et al. Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease. Animal and Translational Models for CNS Drug Discovery. 2008: 93–157.
  14. Müller C, Schibli R. Single photon emission computed tomography tracer. Recent Results Cancer Res. 2013; 187: 65–105.
  15. http://ww5.komen.org/uploadedFiles/Content_Binaries/Chemotherapy%20and%20Side%20Effects%20-%20KOMEED082000.pdf.
  16. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=0ahUKEwjVwMrr59_RAhWB1iwKHTMmAGoQFggeMAA&url=http%3A%2F%2Fwww.nhs.uk%2Fipgmedia%2FNational%2FBreast%2520Cancer%2520Now%2Fassets%2FBesttreatmentguidelines-treatment-adjuvant(B26pages).pdf&usg=AFQjCNGOFn2n0re-C3I-WXgquQW-W3jIgg&bvm=bv.145063293,bs.1,d.bGs.
  17. Chemotherapy for breast cancer. http://www.nhs.uk/ipgmedia/nation-al/breast%20cancer%20care/assets/chemotherapyforbreastcancerbc-c23pages.pdf.
  18. Lapińska G, Kozłowicz-Gudzińska I, Sackiewicz-Słaby A. Equilibrium radionuclide ventriculography in the assessment of cardiotoxicity of chemotherapy and chemoradiotherapy in patients with breast cancer. Nucl Med Rev Cent East Eur. 2012; 15(1): 26–30.
  19. Aghaee F, Islamian JP, Baradaran B, et al. Enhancing the Effects of Low Dose Doxorubicin Treatment by the Radiation in T47D and SKBR3 Breast Cancer Cells. J Breast Cancer. 2013; 16(2): 164–170.
  20. Rizvi F, Bokhari T, Roohi S, et al. Direct labeling of doxorubicin with technetium-99m: its optimization, characterization and quality control. Journal of Radioanalytical and Nuclear Chemistry. 2012; 293(1): 303–307.
  21. Kumar P, Singh B, Sharma S, et al. Preclinical evaluation of [99m]Tc-labeled doxorubicin as a potential scintigraphic probe for tumor imaging. Cancer Biother Radiopharm. 2012; 27(3): 221–225.
  22. Ahmad I, Mustafa E, Mustafa N, et al. 2DG enhances the susceptibility of breast cancer cells to doxorubicin. Open Life Sciences. 2010; 5(6).
  23. Ferro-Flores G, Ocampo-García BE, Santos-Cuevas CL, et al. Multifunctional radiolabeled nanoparticles for targeted therapy. Curr Med Chem. 2014; 21(1): 124–138.
  24. Psimadas D, Bouziotis P, Georgoulias P, et al. Radiolabeling approaches of nanoparticles with (99m) Tc. Contrast Media Mol Imaging. 2013; 8(4): 333–339.
  25. Liang Z, Li X, Xie Y, et al. 'Smart' gold nanoshells for combined cancer chemotherapy and hyperthermia. Biomed Mater. 2014; 9(2): 025012.
  26. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004; 56(11): 1649–1659.
  27. Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials. 2009; 30(29): 5737–5750.
  28. Yezhelyev MV, Gao X, Xing Y, et al. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2006; 7(8): 657–667.
  29. Mitra S, Gaur U, Ghosh PC, et al. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release. 2001; 74(1-3): 317–323.
  30. Jiang X, Xin H, Ren Q, et al. Nanoparticles of 2-deoxy-d-glucose functionalized poly (ethylene glycol)-co-poly (trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials. 2014; 35(1): 518–529.
  31. Xiong F, Zhu Zy, Xiong C, et al. Preparation, characterization of 2-deoxy-D-glucose functionalized dimercaptosuccinic acid-coated maghemite nanoparticles for targeting tumor cells. Pharm Res. 2012; 29(4): 1087–1097.
  32. Okarvi SM, Al Jammaz I. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors. Nucl Med Biol. 2010; 37(3): 277–288.
  33. Ozgur A, Lambrecht FY, Ocakoglu K, et al. Synthesis and biological evaluation of radiolabeled photosensitizer linked bovine serum albumin nanoparticles as a tumor imaging agent. Int J Pharm. 2012; 422(1-2): 472–478.
  34. Polyak A, Palade EA, Balogh L, et al. In vitro and biodistribution examinations of Tc-99m-labelled doxorubicin-loaded nanoparticles. Nucl Med Rev Cent East Eur. 2011; 14(2): 55–62.
  35. Grosso M, Imran MB, Volterrani D, et al. Detection of bilateral, multifocal breast cancer and assessment of tumour response to neoadjuvant chemotherapy by Tc-99m sestamibi imaging - a case report. Nucl Med Rev Cent East Eur. 2008; 11(2): 70–72.
  36. Buscombe JR, Cwikła JB, Thakrar DS, et al. Scintimammography: a review. Nucl Med Rev Cent East Eur. 1999; 2(1): 36–41.